Synthesis of chiral 1-[ω(4-chlorophenoxy)alkyl]-4-methylpiperidines and their biological evaluation at σ1, σ2, and sterol δ8-δ7 isomerase sites

Journal of Medicinal Chemistry

Volumn 46, Issue 11, 2003, Pages 2117-2124

  Berardi, Francesco ^a   Loiodice, Fulvio ^a   Fracchiolla, Giuseppe ^a   Colabufo, Nicola Antonio ^a   Perrone, Roberto ^a   Tortorella, Vincenzo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(4 CHLOROPHENOXY)PIPERIDINE; 1 [3 (4 CHLOROPHENOXY)PROPYL] 4 METHYLPIPERIDINE; 1 [OMEGA (4 CHLOROPHENOXY)] 4 METHYLPIPERIDINE; 4 METHYL 1 [2 (4 CHLOROPHENOXY) 1 METHYLETHYL]PIPERIDINE; 4 METHYL 1 [2 (4 CHLOROPHENOXY)ETHYL]PIPERIDINE; 4 METHYL 1 [2 (4 CHLOROPHENOXY)PROPYL]PIPERIDINE; 4 METHYL 1 [3 (4 CHLOROPHENOXY) 1 METHYLPROPYL]PIPERIDINE; 4 METHYL 1 [3 (4 CHLOROPHENOXY) 2 METHYLPROPYL]PIPERIDINE; 4 METHYL 1 [3 (4 CHLOROPHENOXY)BUTYL]PIPERIDINE; 4 METHYL 1 [3 (4 CHLOROPHENOXY)PROPYL]PIPERIDINE; ALKYL GROUP; ETHYLENE DERIVATIVE; ISOMERASE; METHYL GROUP; OXYETHYLENE; PIPERIDINE DERIVATIVE; RADIOLIGAND; SIGMA 1 ISOMERASE; SIGMA 2 ISOMERASE; STEROL DELTA 7 ISOMERASE; STEROL DELTA 8 ISOMERASE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BINDING SITE; CENTRAL NERVOUS SYSTEM DISEASE; CHIRALITY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYMATIC ASSAY; IN VITRO STUDY; LIGAND BINDING; NEUROPATHY; NONHUMAN;

ANIMALS; BINDING SITES; GUINEA PIGS; LIGANDS; MALE; PIPERIDINES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, SIGMA; STEREOISOMERISM; STEROID ISOMERASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0038248846     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm021014d     Document Type: Article

References (61)

1. Walker, J. M.; Bowen, W. D.; Walker, F. O.; Matsumoto, R. R.; de Costa, B.; Rice, K. C. Sigma receptors: biology and function. Pharmacol. Rev. 1990, 42, 355-402.
2. Tam, S. W. Potential therapeutic application of sigma receptor antagonists. In The sigma receptors; Itzhak, Y., Ed.; Academic Press: London, 1994; pp 191-195.
3. Snyder, S. H.; Largent, B. L. Receptor mechanisms in antipsychotic drug action: focus on sigma receptors. J. Neuropsych. Clin. Neurosci. 1989, 1, 7-15.
4. Frieboes, R. M.; Murck, H.; Wiedemann, K.; Holsboer, F.; Steiger, A. Open clinical trial on the sigma ligand panamesine in patients with schizophrenia. Psychopharmacology 1997, 132, 82-88.
5. Helmeste, D. M.; Tang, S. W.; Bunney, W. E., Jr.; Potkin, S. G.; Jones, E. G. Decrease in σ but no increase in striatal dopamine D4 sites in schizophrenic brains. Eur. J. Pharmacol. 1996, 314, R3-R5.
6. Quirion, R.; Bowen, W. D.; Itzhak, Y.; Junien, J. L.; Musacchio, J. M.; Rothman, R. B., Su, T.-P.; Tam, S. W.; Taylor, D. P. A proposal for the classification of sigma binding sites. Trends Pharmacol. Sci. 1992, 13, 85-86.
7. Debonnel, G.; de Montigny, C. Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci. 1996, 58, 721-734.
8. 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 1994, 268, 9-18.
9. Wolfe, S. A., Jr.; De Souza, E. B. Role of sigma binding sites in the modulation of endocrine and immune functions. In The sigma receptors; Itzhak, Y., Ed.; Academic Press: London, 1994; pp 287-317.
10. Bem, W. T.; Thomas, G. E.; Mamone, J.Y.; Homan, S. M.; Levy, B. K.; Johnson, F. E.; Coscia, C. J. Overexpression of σ receptors in nonneural human tumors. Cancer Res. 1991, 51, 6558-6562.
11. Vilner, B. J.; John, C. S.; Bowen, W. D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995, 55, 408-413.
12. Wilke, R. A.; Mehta, R. P.; Lupardus, P. J.; Chen, Y.; Ruoho, A. E.; Jackson, M. B. Sigma receptor photolabeling and sigma receptor-mediated modulation of potassium channels in tumor cells. J. Biol. Chem. 1999, 274, 18387-18392.
13. 1 receptor function: behavioral consequences and therapeutic opportunities. Brain Res. Rev. 2001, 37, 116-132.
14. Kobayashi, T.; Matsuno, K.; Murai, M.; Mita, S. Sigma 1 receptor subtype is involved in the facilitation of cortical dopaminergic transmission in the rat brain. Neurochem. Res. 1997, 22, 1105-1109.
15. Bermack, J. E.; Debonnel, G. Modulation of serotonergic neurotransmission by short- and long-term treatments with sigma ligands. Br. J. Pharmacol. 2001, 134, 691-699.
16. Bowen, W. D.; Tolentino, P. J.; Hsu, K. K.; Cutts, J. M.; Naidu, S. S. Inhibition of the cholinergic phosphoinositide response by sigma ligands: distinguishing a sigma receptor-mediated mechanism from a mechanism involving direct cholinergic antagonism. In Multiple Sigma and PCP Receptor Ligands: Mechanism for Neuromodulation and Neuroprotection? Kamenka, J.-M., Domino, E. F., Eds.; NPP Books: Ann Arbor, MI, 1992; pp 155-167.
17. 1 receptor modulation of opioid analgesia in the mouse. J. Pharmacol. Exp. Ther. 2002, 300, 1070-1074.
18. Connick, J. H.; Hanlon, G.; Roberts, J.; France, L.; Fox, P. K.; Nicholson, C. D. Multiple σ binding sites in guinea-pig and rat brain membranes: G-protein interactions. Br. J. Pharmacol. 1992, 107, 726-731.
19. 3 dorsal hippocampus neurones are differentially affected by pertussis toxin. Br. J. Pharmacol. 1994, 112, 709-715.
20. Aydar, E.; Palmer, C. P.; Klyachko, V. A.; Jackson, M. B. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 2002, 34, 399-410.
21. Moebius, F. F.; Striessnig, J.; Glossmann, H. The mysteries of sigma receptors: new family members reveal a role in cholesterol synthesis. Trends Pharmacol. Sci. 1997, 18, 67-70.
22. 1 receptor at endoplasmic reticulum and nuclear envelope level. Eur. J. Biochem. 1999, 263, 377-385.
23. Bowen, W. D. Sigma receptors: recent advances and new clinical potentials. Pharm. Acta Helv. 2000, 74, 211-218.
24. Vilner, B. J.; Bowen, W. D. Modulation of cellular calcium by Sigma-2 receptors: Release from intracellular stores in human SK-N-SH neuroblastoma cells. J. Pharmacol. Exp. Ther. 2000, 292, 900-911.
25. Walker, J. M.; Bowen, W. D.; Patrick, S. L.; Williams, W. E.; Mascarella, S. W.; Bai, X.; Carroll, F. I. A comparison of (-)-deoxybenzomorphans devoid of opiate activity with their dextrorotatory phenolic counterparts suggests a role of sigma-2 receptors in motor function. Eur. J. Pharmacol. 1993, 231, 61-68.
26. Matsumoto, R. R.; Bowen, W. D.; Tom, M. A.; Nhi Vo, V.; Truong, D. D.; de Costa, B. R. Characterization of two novel σ receptor ligands: antidystonic effects in rats suggest σ receptor antagonism. Eur. J. Pharmacol. 1995, 280, 301-310.
27. Jeanjean, A. P.; Laterre, E. C.; Maloteaux, J. M. Neuroleptic binding to sigma receptors: possible involvement in neurolepticinduced acute dystonia. Biol. Psych. 1997, 41, 1010-1019.
28. 2 receptors and acute dystonic reactions. Eur. J. Pharmacol. 2000, 401, 155-160.
29. 1) receptor agonists confirmed by in vivo antisense strategy in the mouse. Brain Res. 2001, 898, 113-121.
30. Maurice, T.; Lockhart, B. P. Neuroprotective and antiamnesic potentials of σ (sigma) receptor ligands. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 1997, 21, 69-102.
31. Nishikawa, H.; Hashino, A.; Kume, T.; Katsuki, H.; Kaneko, S.; Akaike, A. Involvement of direct inhibition of NMDA receptors in the effects of σ-receptor ligands on glutamate neurotoxicity in vitro. Eur. J. Pharmacol. 2000, 404, 41-48.
32. Matsumoto, R. R.; McCracken, K. A.; Pouw, B.; Miller, J.; Bowen, W. D.; Williams, W.; De Costa, B. R. N-alkyl substituted analogs of the σ receptor ligand BD1008 and traditional σ receptor ligands affect cocaine-induced convulsions and lethality in mice. Eur. J. Pharmacol. 2001, 411, 261-273.
33. 1 receptors produce anti-cocaine effects in mice. Eur. J. Pharmacol. 2001, 419, 163-174.
34. Muller, M. J.; Grunder, G.; Wetzel, H.; Muller-Siecheneder, F.; Marx-Dannigkeit, P.; Benkert, O. Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial. Psychiatry Res. 1999, 89, 275-280.
35. 1) receptor: pharmacological evidence and therapeutic opportunities. Jpn. J. Pharmacol. 1999, 81, 125-155.
36. Caveliers, V.; Everaert, H.; Lahoutte, T.; Dierickx, L. O.; John, C. S.; Bossuyt, A. Labelled sigma receptor ligands: can their role in neurology and oncology be extended? Eur. J. Nucl. Med. 2001, 28, 133-135.
37. 3H]MS-377, a novel σ receptor ligand, to rat brain membranes. Eur. J. Pharmacol. 2000, 400, 51-57.
38. Takahashi, S.; Sonehara, K.; Takagi, K.; Miwa, T.; Horikomi, K.; Mita, N.; Nagase, H.; Iizuka, K.; Sakai, K. Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for σ receptors. Psychopharmacology 1999, 145, 295-302.
39. Guitart, X.; Ballarin, M.; Codony, X.; Dordal, A.; Farré, A. J.; Frigola, J.; Mercè, R. E-5842. Drugs Future 1999, 24, 386-392.
40. Maeda, D. Y.; Williams, W.; Bowen, W. D.; Coop, A. A Sigma-1 Receptor Selective Analogue of BD 1008. A Potential Substitute for (+)-Opioids in Sigma Receptor Binding Assays. Bioorg. Med. Chem. Lett. 2000, 10, 17-18.
41. Nakazato, A.; Otha, K.; Sekiguchi, Y.; Okuyama, S.; Chaki, S.; Kawashima, Y.; Hatayama, K. Design, Synthesis, StructureActivity Relationships, and Biological Characterization of Novel Arylalkoxyphenylalkylamine σ ligands as Potential Antipsychotic Drugs. J. Med. Chem. 1999, 42, 1076-1087.
42. Nishimura, T.; Katsumi, H.; Nakayama, H.; Sunagawa, J. Sigma receptor-binding piperidines and agents containing them for treatment of mental and neurological disorders. Sumitomo Chemical Co., Ltd., Japan Patent JP 10231245, 1998; Drug Data Report 1998, 20, 921; C. A. 1998, 129, 255003c.
43. Nishimura, T.; Katsumi, H.; Nakayama, H.; Sunagawa, J. Sigma receptor-binding piperidines and agents containing them for treatment of mental and neurological disorders. Sumitomo Chemical Co., Ltd., Japan Patent JP 10231245, 1998; Drug Data Report 1998, 20, 921; C. A. 1998, 129, 255003c.
44. Nishimura, T.; Katsumi, H.; Nakayama, H.; Sunagawa, J. Sigma receptor-binding piperidines and agents containing them for treatment of mental and neurological disorders. Sumitomo Chemical Co., Ltd., Japan Patent JP 10231245, 1998; Drug Data Report 1998, 20, 921; C. A. 1998, 129, 255003c.
45. Ablordeppey, S. Y.; Fischer, J. B.; Burke Howie, K. J.; Glennon, R. A. Design, synthesis and binding of sigma receptor ligands derived from butaclamol. Med. Chem. Res. 1992, 2, 368-375.
46. Ablordeppey, S. Y.; Issa, H.; Fischer, J. B.; Burke Howie, K. J.; Glennon, R. A. Synthesis and structure-affinity relationship studies of sigma ligands related to haloperidol. Med. Chem. Res. 1993, 3, 131-138.
47. Ablordeppey, S. Y.; Fischer, J. B.; Glennon, R. A. Is a Nitrogen Atom an Important Pharmacophoric Element in Sigma Ligand Binding? Bioorg. Med. Chem. 2000, 8, 2105-2111.
48. Carroll, F. I.; Abraham, P.; Parham, K.; Bai, X.; Zhang, X.; Brine, G. A.; Mascarella, S. W.; Martin, B. R.; May, E. L.; Sauss, C.; Di Paolo, L.; Wallace, P.; Walker, J. M.; Bowen, W. D. Enantiomeric N-Substituted N-Normetazocines: A Comparative Study of Affinities at σ, PCP and μ Opioid Receptors. J. Med. Chem. 1992, 35, 2812-2818.
49. May, E. L.; Jacobson, A. E.; Mattson, M. V.; Traynor, J. R.; Woods, J. H.; Harris, L. S.; Bowman, E. R.; Aceto, M. D. Synthesis and in Vitro and in Vivo Activity of (-)-(1R,5R,9R)and (+)41S,5S,9S)-N-Alkenyl-, -N-Alkynyl-, and -N-Cyanoalkyl5,9-dimethyl-2′-hydroxy-6,7-benzomorphan Homologues. J. Med. Chem. 2000, 43, 5030-5036.
50. Danso-Danquah, R.; Bai, X.; Zhang, X.; Mascarella, S. W.; Williams, W.; Sine, B.; Bowen, W. D.; Carroll, F. I. Synthesis and σ Binding Properties of 2′-Substituted 5,9a-Dimethyl-6,7benzomorphans. J. Med. Chem. 1995, 38, 2978-2985.
51. Carroll, F. I.; Bai, X.; Dehghani, A.; Mascarella, S. W.; Williams, W.; Bowen, W. D. Asymmetric synthesis of 9-alkyl-2-benzyl-6,7-benzomorphans: characterization as novel σ receptor ligands. J. Med. Chem. 1999, 42, 4621-4629.
52. 1 and EBP Sites. Bioorg. Med. Chem. 2001, 9, 1325-1335.
53. Mitsunobu, O. The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products. Synthesis 1981, 1-28.
54. Loiodice, F.; Ferorelli, S.; Tangari, N.; Bettoni, G.; Tortorella, V.; Pierno, S.; De Luca, A.; Tricarico, D.; Conte-Camerino, D. Carboxylic Acids and Chloride Conductance in Skeletal Muscle: Influence on the Pharmacological Activity Induced by the Chain Substituents and the Distance Between the Phenolic Group and the Carboxylic Function in 4-Chloro-Phenoxy Al-kanoic Acids. II Farmaco 1993, 48, 45-63.
55. Bose, A. K.; Greer, F.; Price, C. C. A Procedure For Phthaloylation under Mild Conditions. J. Org. Chem. 1958, 23, 1335-1338.
56. Besse, P.; Ciblat, S.; Canet, J.-L.; Troin, Y.; Veschambre, H. Stereoselective Chemoenzymatic Synthesis of Both Enantiomers of Protected 4-Amino-2-Pentanone. Tetrahedron: Asymmetry 1999, 10, 2213-2224.
57. Louwrier, S.; Ostendorf, M.; Boom, A.; Hiemstra, H.; Speckamp, W. N. Studies Towards the Synthesis of (+)-Ptilomycalin A.; Stereoselective N-Acyliminium Ion Coupling Reactions to Enantiopure C-2 Substituted Lactams. Tetrahedron 1996, 52, 2603-2628.
58. Carocci, A.; Catalano, A.; Corbo, F.; Duranti, A.; Amoroso, R.; Franchini, C.; Lentini, G.; Tortorella, V. Stereospecific Synthesis of Mexiletine and Related Compounds: Mitsunobu Versus Williamson Reaction. Tetrahedron: Asymmetry 2000, 11, 3619-3634.
59. GraphPad Prism Software (version for Windows), GraphPad Software, Inc.: San Diego, CA.
60. Bettoni, G.; Loiodice, F.; Tortorella, V.; Conte-Camerino, D.; Mambrini, M.; Ferrannini, E.; Bryant, S. H. Stereospecificity of the Chloride Ion Channel: the Action of Chiral Clofibric Acid Analogues. J. Med. Chem. 1987, 30, 1267-1270.
61. 2+ antagonist binding protein from guinea pig liver endoplasmic reticulum. J. Biol. Chem. 1994, 269, 29314-29320.